China’s NMPA Announces Good Practices for Review Timelines During the Drug Evaluation Process
China’s NMPA Announces Good Practice for Timing Termination and Restoration of Review in the Process of Drug Evaluation
- About GRP
- Countries
- Canada’s Health Canada
- United States’ FDA
- Brazil
- Mexico’s COFEPRIS
- Europe’s EMA
- Australia
- China
- Japan’s PMDA
- Korea’s Ministry of Food and Drug Safety (MFDS)
- Taiwan’s Food and Drug Administration (TFDA)
- Singapore’s HSA
- India’s CDSCO
- Services
- Resource Center
- RI Platform
- Japan Regulatory Intelligence (RI)
- China (NMPA) Regulatory Intelligence
- Brazil
- Mexico Regulatory Intelligence (RI)
- USA Regulatory Intelligence (RI)
- Contact Us
Menu